CAPR Stock Analysis: Buy, Sell, or Hold?
CAPR - Capricor Therapeutics Inc
$22.22
-0.21 (-0.94%)
▼
5d:
-6.64%
30d:
-20.5%
90d:
-29.86%
HOLD
LOW Confidence
Analysis Updated: Jul 7, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Smart Money Accumulation
None View Scanner →
Strength: 9.9/10
Get Alerted When CAPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
30 traders called CAPR this week
92% bullish • 3 bearish
92% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CAPR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CAPR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CAPR is currently trading at $22.22, which is considered oversold relative to its 30-day fair value range of $24.18 to $28.87. From a valuation perspective, the stock is trading at a discount (Forward PE: -34.6) compared to its historical average (133.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAPR is in a strong downtrend. The price is currently testing key support at $21.64. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CAPR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $53.60 (+141.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CAPR is in a strong downtrend. The price is currently testing key support at $21.64. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CAPR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $53.60 (+141.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.18 -
$28.87
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
Protect Your Profits
Holding CAPR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 141.2% below Wall St target ($53.60)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -6.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$24.18 -
$28.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$21.65
Resistance Level
$30.93
Current Trend
Strong Downtrend
Technical data as of
Jul 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-34.60
Wall Street Target
$53.60
(+141.2%)
Revenue Growth (YoY)
-7.9%
PE vs Historical
-34.6 vs 133.6
CHEAP
Share & Embed Analysis
Last updated: July 07, 2026 8:32 PM ET
Data refreshes hourly during market hours. Next update: 9:32 PM
Data refreshes hourly during market hours. Next update: 9:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Karimah Es Sabar
SELL
7529 shares
2026-04-02
Karimah Es Sabar
SELL
53735 shares
2026-04-01
Anthony Bergmann
SELL
25000 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 55 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 63 BUY |
Advanced CAPR Option Strategies
Professional options setups generated by AI based on today's CAPR price and gamma walls.
